Report Highlights

Understanding SBRT: A Buyer's Overview

Stereotactic body radiation therapy delivers highly concentrated radiation doses to tumors with sub-millimeter precision, typically across one to five treatment fractions. The primary buyers are hospital-based radiation oncology departments, freestanding cancer centers, and academic medical institutions. Procurement involves capital equipment — linear accelerators (linacs), treatment planning systems, and immobilization devices — alongside multi-year service contracts, software licensing, and clinical integration support. This category sits at the intersection of oncology infrastructure and medical technology, requiring coordination between clinical, technical, and finance teams before any purchasing decision is finalised.

The SBRT supplier landscape is moderately concentrated. Varian (now Siemens Healthineers) and Elekta collectively account for the majority of global linac installations, with Accuray holding a meaningful niche through its CyberKnife and Radixact platforms. Competitive tenders are standard for public hospital procurement in Europe and Asia Pacific, while U.S. health systems often operate through group purchasing organizations or direct capital negotiation. Contract lengths for service agreements typically run three to five years, with equipment replacement cycles extending seven to ten years. Pricing models combine upfront capital purchase or lease with annual service contracts priced as a percentage of equipment value.

Factors Driving SBRT Procurement

Three specific forces are pushing SBRT budget allocation higher right now. First, the expansion of Medicare reimbursement for prostate SBRT — specifically the 2023 CMS coverage determination supporting five-fraction prostate treatment — has unlocked procurement decisions at community hospital systems that previously deferred investment. This reimbursement clarity directly reduces financial risk for administrators approving capital requests. Second, escalating demand for outpatient oncology capacity is pushing health systems to add SBRT capability as a patient retention and revenue diversification strategy, particularly for lung cancer screening programs generating Stage I diagnoses that are surgical candidates.

Third, the growth of oligometastatic disease treatment protocols — supported by landmark SABR-COMET trial data showing survival benefit in controlled oligometastatic settings — is expanding SBRT's clinical indication base well beyond its original early-stage lung cancer application. Oncology programs that previously justified a single SBRT-capable unit are now evaluating second-unit capacity to absorb referral volumes. Regulatory harmonization across the EU, specifically the updated EURATOM directive requirements for treatment planning system validation and dosimetric audit, is also forcing European centers to upgrade older linac platforms that lack native adaptive planning or motion management integration.

Challenges Buyers Face in SBRT Procurement

The most significant procurement challenge in SBRT is accurately forecasting total cost of ownership beyond the initial capital purchase. Equipment list prices for a fully configured SBRT-capable linac typically range from USD 3 million to over USD 5 million, but buyers frequently underestimate the cost of the treatment planning system license, network infrastructure for DICOM data management, physics commissioning time, and ongoing annual software subscription fees. Service contract escalators of 3–5% annually are standard, and unplanned downtime on a single-unit department can represent significant revenue loss that is rarely captured in the business case presented to finance committees.

Vendor lock-in presents a structural challenge specific to this market. Treatment planning systems — particularly Varian's Eclipse and Elekta's Monaco — are deeply embedded in clinical workflows, and switching costs extend well beyond software licensing to include re-training dosimetrists and physicists, re-commissioning beam models, and re-validating institutional treatment protocols. Buyers who negotiate equipment contracts without simultaneously addressing TPS licensing terms frequently find themselves paying premium renewal rates at the five-year mark. Supplier concentration also creates risk: if a facility's entire SBRT program depends on a single-vendor linac and that vendor experiences a global parts shortage — as occurred with multiple manufacturers during 2021–2022 — treatment scheduling is directly compromised.

Emerging Opportunities Worth Watching in SBRT

Artificial intelligence-driven auto-contouring and automated treatment planning represent the most operationally significant near-term opportunity for SBRT buyers. Vendors including Varian, Elekta, and RaySearch Laboratories are embedding AI planning tools that can reduce SBRT plan generation time from hours to under thirty minutes. For high-volume programs processing twenty or more SBRT patients per week, this throughput gain has direct financial value. Buyers who negotiate access to these AI modules as part of initial TPS contracts — rather than as post-installation add-ons — will achieve meaningful workflow cost reductions within the 2026–2028 window.

Surface-guided radiation therapy (SGRT) integration with SBRT workflows is a second area deserving procurement attention. Systems from C-RAD and Vision RT are increasingly being specified as standard components in new SBRT suite builds rather than optional upgrades, driven by growing clinical evidence for improved intrafraction motion detection in thoracic and abdominal SBRT. A third development is the emergence of subscription-based linac procurement models offered by Siemens Healthineers and Elekta in select markets, which distribute capital expenditure into operational budgets. For health systems facing constrained capital access, this model changes the procurement calculus entirely and merits evaluation before initiating a traditional capital purchase process.

How to Evaluate SBRT Suppliers

Three evaluation criteria are genuinely differentiated in this market. First, assess adaptive planning capability under real clinical throughput conditions — request a live workflow demonstration using your institution's actual case complexity and caseload volume, not a vendor-curated phantom study. Second, evaluate the vendor's physics support infrastructure: the quality and response time of regional application specialists and medical physics support directly determines how quickly your team achieves clinical competency and program productivity post-installation. Third, scrutinize the service contract structure specifically for parts availability commitments and guaranteed mean time to repair, since downtime SLAs vary significantly between vendors and are rarely enforced without explicit contractual language.

The most common evaluation mistake buyers make in this market is selecting a platform based on a reference site visit to a flagship academic center whose clinical volume, physics staffing, and IT infrastructure are entirely unrepresentative of the buying institution. A supplier that performs excellently at MD Anderson or the Royal Marsden does not necessarily deliver equivalent support to a community cancer center with one medical physicist. Buyers should request references specifically from institutions of comparable size and case mix. Additionally, buyers consistently fail to evaluate the TPS vendor independently of the linac vendor — the treatment planning system contract has a longer functional lifespan than the equipment and should be negotiated and benchmarked as a separate procurement decision.

Market at a Glance

Regional Demand: Where SBRT Buyers Are

North America is the most mature SBRT buyer market globally, accounting for the largest share of installed linac capacity configured for SBRT delivery. The United States drives the majority of this demand, underpinned by strong reimbursement infrastructure, high lung cancer screening enrollment, and a large base of freestanding radiation oncology centers that compete aggressively on clinical capability. Canada is adding SBRT capacity through provincial cancer program capital cycles, though procurement timelines in the public system are significantly longer than in the U.S. private sector. Supplier availability and application support are stronger in North America than in any other region, making competitive negotiations more viable for buyers here.

Europe represents the second-largest demand base, with Germany, the United Kingdom, France, and the Netherlands leading in SBRT program maturity. European buyers operate under more prescriptive regulatory frameworks regarding treatment planning system validation and dosimetric audit requirements, which narrows the pool of compliant vendors but also creates clearer evaluation criteria. Asia Pacific is the fastest-growing SBRT procurement region, led by Japan, China, South Korea, and Australia. Japan's National Health Insurance expansion of SBRT reimbursement for liver and lung indications has triggered significant capital investment across prefectural hospitals. China's national oncology infrastructure development program is driving linac procurement at scale, although domestic vendors such as Neusoft Medical are beginning to compete meaningfully against Varian and Elekta for lower-acuity installations.

Leading Market Participants

• Varian Medical Systems (Siemens Healthineers)
• Elekta AB
• Accuray Incorporated
• ViewRay
• Brainlab AG
• RaySearch Laboratories
• C-RAD AB
• Vision RT
• Neusoft Medical Systems
• IBA (Ion Beam Applications)

What Comes Next for SBRT

The most consequential change buyers should plan for over the next three to five years is the transition from static to fully adaptive SBRT delivery, where the treatment plan is modified in real time based on daily imaging acquired at the treatment unit. This is not a marginal workflow refinement — it requires new physics QA protocols, additional staff training, and software infrastructure that many current linac installations do not natively support. Regulatory bodies in the U.S. and EU are beginning to develop guidance on adaptive radiotherapy quality standards, which will eventually create compliance requirements that force platform upgrades across programs that deferred investment in adaptive capability.

Supplier consolidation is a second structural shift buyers must anticipate. The acquisition of Varian by Siemens Healthineers has already altered the competitive dynamics of the SBRT capital market, and further consolidation — whether through additional acquisitions or partnership agreements between linac vendors and TPS developers — will reduce buyer negotiating leverage. Buyers entering capital refresh cycles in 2025 and 2026 should lock in multi-year service pricing, software upgrade commitments, and trade-in value guarantees before consolidation further reduces competitive alternatives. Programs planning new SBRT suite builds should specify AI-ready infrastructure and SGRT conduit preparation as baseline construction requirements, not future-phase add-ons, to avoid costly retrofitting within five years.

Market Segmentation

By Product Type

• Linear Accelerators (Linacs)
• Robotic Radiosurgery Systems
• Treatment Planning Systems
• Immobilization Devices
• Surface-Guided RT Systems
• Imaging and Guidance Systems

By Indication

• Lung Cancer
• Prostate Cancer
• Liver Cancer
• Spinal Tumors
• Pancreatic Cancer
• Oligometastatic Disease

By End User

• Hospital-Based Radiation Oncology Centers
• Freestanding Cancer Centers
• Academic Medical Institutions
• Ambulatory Surgical Centers

By Technology

• Image-Guided SBRT (IGRT)
• Adaptive SBRT
• MR-Guided SBRT
• Robotic SBRT (CyberKnife)
• Proton-Based SBRT

Frequently Asked Questions

Q1. What is the typical capital budget required to establish a new SBRT program from scratch? ▼

A fully configured SBRT-capable linac with treatment planning system, simulation CT, and immobilization equipment typically requires USD 5–8 million in capital, excluding facility construction and commissioning costs. Physics commissioning alone commonly requires three to six months before the first patient is treated.

Q2. How long does it take to operationalize an SBRT program after equipment delivery? ▼

From equipment delivery to first clinical treatment, most institutions require six to twelve months, depending on the availability of qualified medical physics staff and the complexity of the institutional treatment protocol library. Programs hiring external physics commissioning support can compress this timeline to four to six months.

Q3. What reimbursement landscape should procurement teams understand before approving SBRT investment? ▼

In the United States, CMS reimburses SBRT under specific CPT codes with per-fraction rates that vary by indication, and the 2023 prostate SBRT coverage expansion materially improved program financial viability. European reimbursement remains fragmented by country, and buyers should conduct a country-specific payer analysis before finalizing business case projections.

Q4. How should buyers assess vendor service quality before signing a multi-year service contract? ▼

Request the vendor's documented mean time to repair data for your specific equipment model across institutions in your region, and require contractual language specifying maximum downtime thresholds with financial penalties for breach. Reference checks with institutions of comparable size and caseload are more informative than manufacturer-provided satisfaction surveys.

Q5. Is it better to procure the linac and treatment planning system from the same vendor? ▼

Single-vendor procurement simplifies integration support and accountability but creates dependency that weakens renegotiation leverage at contract renewal. Procuring the TPS independently from vendors such as RaySearch Laboratories preserves competitive pressure and often provides access to more advanced planning algorithm updates ahead of proprietary vendor TPS releases.